Survey of atypical antipsychotic medication use by child and adolescent psychiatrists

Child and Adolescent Mental Health

Volumn 11, Issue 3, 2006, Pages 164-167

  Sivaprasad, Leela ^a   Hassan, Tariq ^a   Handy, Sumi ^b  

^a Birmingham Children's Hospital ^*  (United Kingdom)

^b BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Atypical antipsychotics; Children and adolescents; Prescribing; Survey

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

AGGRESSION; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; BEHAVIOR DISORDER; CHILD HEALTH CARE; CHILD PSYCHIATRY; CHILDHOOD DISEASE; CLINICAL PRACTICE; CONDUCT DISORDER; DEPRESSION; DOSE RESPONSE; DRUG MONITORING; DRUG RESEARCH; DRUG USE; HUMAN; LEARNING DISORDER; MENTAL DISEASE; OBSESSIVE COMPULSIVE DISORDER; PRESCRIPTION; PRIORITY JOURNAL; PSYCHIATRIST; PSYCHOSIS; SCHIZOPHRENIA;

EID: 33747593566     PISSN: 1475357X     EISSN: 14753588     Source Type: Journal    
DOI: 10.1111/j.1475-3588.2006.00404.x     Document Type: Article

References (22)

1. Andres, M., & Douglas, L. (2003). Trends in psychotropic medication costs for children and adolescents, 1997-2000. Archives of Pediatrics and Adolescent Medicine, 157, 997-1007.
2. Armenteros, J.L., Whitaker, A.H., Welikson, M., Stedge, D.J., & Gorman, J. (1997). Risperidone in adolescents with schizophrenia: An open pilot study. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 694-700.
3. Campbell, M., Rapoport, J., & Simpson, G. (1999). Antipsychotics in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 38, 537-545.
4. Coghill, D. (2003a). Current issues in child and adolescent psychopharmacology. Part 1: Attention-deficit hyperactivity and affective disorders. Advances in Psychiatric Treatment, 9, 86-94.
5. Coghill, D. (2003b). Current issues in child and adolescent psychopharmacology. Part 2: Anxiety and obsessive-compulsive disorders, autism, Tourette's and schizophrenia. Advances in Psychiatric Treatment, 9, 289-299.
6. Doerry, U., & Kent, L. (2003). Prescribing practices of community child and adolescent psychiatrists. Psychiatric Bulletin, 27, 407-410.
7. Findling, R.L., McNamara, N.K., & Gracious, B.L. (2000). Paediatric uses of atypical antipsychotics. Expert Opinion on Pharmacotherapy, 1, 935-945.
8. Findling, R.L., & McNamara, N.K. (2004). Atypical antipsychotics in the treatment of children and adolescents: Clinical applications. Journal of Clinical Psychiatry, 65 (suppl. 6), 30-44.
9. Jefferson, A-M., Markowitz, J.S., & Brewerton, T.D. (1998). Atypical antipsychotics. Journal of the American Academy of Child and Adolescent Psychiatry, 37, 1243-1244.
10. McCellan, J.M., & Werry, J.S. (2003). Evidence-based treatments in child and adolescent psychiatry: An inventory. Journal of the American Academy of Child and Adolescent Psychiatry, 42, 1388-1400.
11. McIntyre, R., & Katzman, M. (2003). The role of atypical antipsychotics in bipolar depression and anxiety disorders. Bipolar Disorders, Supplement, 5, 20-35.
12. Pappadopulos, E., Jensen, P.S., Schur, B.S., MacIntyre, J.C., Ketner, S., Van Orden, K., Sverd, J., Sardana, S., Woodlock, D., Schweitzer, R., & Rube, D. (2002). 'Real World' atypical antipsychotic prescribing practices in public child and adolescent inpatient settings. Schizophrenia Bulletin, 28, 111-121.
13. Ram, J.R., & Vanstraelen, M. (1999). Use of antipsychotics by child and adolescent psychiatrists (letter). Psychiatric Bulletin, 23, 182-183.
14. Ratzoni, G., Gothelf, D., Brand-Gothelf, A., Reidman, J., Kikinzon, L., Gal. G., Phillip, M., Apter, A., & Weizman, R. (2002). Weight gain associated with Olanzapine and Risperidone in adolescent patients: A comparative prospective study. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 337-343.
15. Riddle, M.A., Kastelic, E.A., & Frosch, E. (2001). Pediatric psychopharmacology. Journal of Child Psychology and Psychiatry, 42, 73-90.
16. Scahill, L., & Lynch, K.A. (1998). Atypical neuroleptics in children and adolescents. Journal of Child and Adolescent Psychiatric Nursing, 11, 38-43.
17. Sharif, Z.A. (2002). Safety of atypical antipsychotics. In, Using atypical antipsychotics in primary care (Academic Highlights). The Primary Care Companion to the Journal of Clinical Psychiatry, 4, 233-241.
18. Sharma, V. (2003). Atypical antipsychotics and suicide in mood and anxiety disorders. Bipolar Disorders, Supplement, 5, 48-52.
19. Slaveska, K., Hollis, C., & Bramble, D. (1998). Use of antipsychotics by child and adolescent psychiatrists. Psychiatric Bulletin, 22, 685-687.
20. Trenton, A.J., Currier, G.W., & Zwemer, F.L. (2003). Fatalities associated with therapeutic use and overdose of atypical antipsychotics. CNS Drugs, 17, 307-324.
21. Vitiello, B., Riddle, M.A., Greenhill, L.L., March, J.S., Levine, J., Schachar, R.J., Abikoff, H., Zito, J.M., McCracken, J.T., Walkup, J.T., Findling, R.L., Robinson, J., Cooper, T.B., Davies, M., Varipatis, E., Labellarte, M.J., Scahill, L., & Capasso, L. (2003). How can we improve the assessment of safety in child and adolescent psychopharmacology ? Journal of the American Academy of Child and Adolescent Psychiatry, 42, 634-641.
22. Woods, S.W., Martin, A., Spector, S.G., & McGlashan, T. H. M. (2002). Effects of development on Olanzapine-associated adverse events. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 1439-1446.